Pfizer Inc. (NYSE:PFE) Stake Lifted by Thompson Investment Management Inc.

Thompson Investment Management Inc. increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 403,464 shares of the biopharmaceutical company’s stock after buying an additional 22,179 shares during the quarter. Pfizer comprises approximately 1.5% of Thompson Investment Management Inc.’s holdings, making the stock its 13th largest position. Thompson Investment Management Inc.’s holdings in Pfizer were worth $10,704,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Entropy Technologies LP grew its stake in shares of Pfizer by 1,488.3% in the fourth quarter. Entropy Technologies LP now owns 471,886 shares of the biopharmaceutical company’s stock worth $12,519,000 after purchasing an additional 442,175 shares in the last quarter. Empowered Funds LLC grew its stake in shares of Pfizer by 72.6% in the fourth quarter. Empowered Funds LLC now owns 877,300 shares of the biopharmaceutical company’s stock worth $23,275,000 after purchasing an additional 369,044 shares in the last quarter. D Orazio & Associates Inc. grew its stake in shares of Pfizer by 5.5% in the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock worth $200,000 after purchasing an additional 391 shares in the last quarter. Kingsview Wealth Management LLC grew its stake in shares of Pfizer by 28.8% in the fourth quarter. Kingsview Wealth Management LLC now owns 159,281 shares of the biopharmaceutical company’s stock worth $4,226,000 after purchasing an additional 35,652 shares in the last quarter. Finally, Vest Financial LLC grew its stake in shares of Pfizer by 15.1% in the fourth quarter. Vest Financial LLC now owns 27,234 shares of the biopharmaceutical company’s stock worth $723,000 after purchasing an additional 3,573 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Truist Financial decreased their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Bank of America reaffirmed a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Sanford C. Bernstein initiated coverage on Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. UBS Group decreased their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Finally, Citigroup decreased their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Trading Down 0.3 %

Shares of NYSE PFE opened at $25.76 on Friday. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a market cap of $145.96 billion, a price-to-earnings ratio of 18.27, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business has a fifty day simple moving average of $26.28 and a 200-day simple moving average of $27.74.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.10 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.68%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio is currently 121.99%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.